MSD and Daiichi Sankyo commence Phase III breast cancer therapy trial
MSD and Daiichi Sankyo have initiated the Phase III HERTHENA-Breast04 clinical trial, with the first subject receiving a dose of…
Women's Health
-
-
Unmet needs in endometriosis: a persistent challenge
The endometriosis therapeutics market continues to face significant unmet needs, primarily due to low diagnosis rates, limited disease awareness, and…
-
Organon discontinues endometriosis drug after Phase II flunk
Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA…
-
Bio-Thera Solutions doses first subject in Phase III ADC ovarian cancer trial
Bio-Thera Solutions has initiated dosing in the randomised Phase III trial of the antibody-drug conjugate (ADC), BAT8006, aimed at treating…
-
Scynexis resumes dosing in Phase III MARIO study after lengthy delay
Scynexis has resumed dosing of its vaginal yeast infection drug Brexafemme (ibrexafungerp) in a Phase III trial after a 19-month…
-
Gilead’s Phase III trial for breast cancer therapy meets primary goal
Gilead Sciences’ randomised, global Phase III ASCENT-03 trial of Trodelvy (sacituzumab govitecan-hziy) has met its primary endpoint, showing improvement in…
-
AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan), followed by paclitaxel, trastuzumab and pertuzumab (THP), has shown pathologic complete response (pCR) rate…
-
Synthetic hormones and the future of contraception
The landscape of contraception for women has seen minimal change over the past 50 years, with successive generations often relying…
-
Gilead reports topline data from Phase III trial of Trodelvy combo therapy
Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy (sacituzumab govitecan-hziy) and MSD’s…
-
Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial
Daiichi Sankyo and AstraZeneca's Enhertu (trastuzumab deruxtecan) with pertuzumab has shown progression-free survival (PFS) improvement in the Phase III DESTINY-Breast09…
